Mochida Pharma President Announces Niche Expansion And Aims For ¥3 Billion Annul Revenue From Generic Drugs
This article was originally published in PharmAsia News
Executive Summary
Segmentation in the pharmaceutical industry creates many areas for mid-sized drug makers to explore, Mochida Pharma President Naoyuki Mochida stated at a press briefing. As a mid-sized enterprise, Mochida's niche in speed and specialization will allow it to compete with industrial giants, Mochida said. In 2008, Mochida Pharma will focus resources on four areas: cardiovascular drugs, obstetrics and gynecology, dermatological treatment and emergency medicines. Establishing strategic alliances with other pharmaceutical companies also creates opportunities to expand. Last February, Mochida Pharma signed a contract with Norvatis to jointly promote the anti-hypertension drug Diovan (valsartan). Regarding the company's generic drug business, Mr. Mochida expects to have a wider selection in products and has a goal of ¥3 billion in annual revenue. (Click here for more-Japanese language